RAG1慢病毒基因治疗在人工胸腺类器官中恢复RAG1-SCID患者细胞的T细胞发育
本研究利用人工胸腺类器官(ATO)系统,观察到健康供者造血干祖细胞可发育为αβ和γδ T细胞;3例RAG1-SCID患者未矫正的造血干祖细胞出现发育阻滞;临床载体介导的RAG1基因添加可恢复患者来源细胞的T细胞发育及TCR库多样性。
要点
- ATO培养支持健康供者脐血或动员外周血来源HSPCs的T细胞发育。
- 未矫正的RAG1缺陷HSPCs在CD4+CD8dim双阳性阶段前或该阶段发育阻滞。
- 临床载体RAG1基因添加可恢复患者HSPCs的T细胞发育和TCR库多样性。
核心结论
- ATO系统是研究人T细胞发育及基因治疗临床前开发与评估的有价值模型。
研究设计与样本
- 本研究采用体外人工胸腺类器官(ATO)培养系统,评估健康供者及3例RAG1-SCID患者来源的造血干祖细胞(HSPCs)。
主要发现
- 健康供者脐血或动员外周血来源的HSPCs在ATO培养中可产生αβ和γδ T细胞,TCR库呈多克隆。
- 3例RAG1-SCID患者未矫正的HSPCs在CD4+CD8dim双阳性阶段前或该阶段发育阻滞,CD1a上调极少或缺失、CD7下调缺失、TCRβ重排缺失、TCRγ和TCRδ仅部分重排。
- 使用临床载体进行慢病毒RAG1基因添加可恢复患者来源HSPCs的T细胞发育并恢复TCR库多样性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recombination activating gene 1 (RAG1) is essential for variable diversity joining recombination during early T- and B-cell development. Null mutations cause a complete block in receptor rearrangement, resulting in T-B- severe combined immunodeficiency (SCID). Patients with RAG1-SCID require hematopoietic stem cell transplantation for survival. Our phase I/II clinical trial (NCT04797260) is currently evaluating lentiviral RAG1 gene addition in autologous hematopoietic stem and progenitor cells (HSPCs). However, studying early human T-cell development is challenging due to limited access to thymic tissue. The artificial thymic organoid (ATO) system offers a promising in vitro model to study human T-cell differentiation. Here, we show that ATO cultures efficiently support T-cell development from healthy donor HSPCs derived from umbilical cord blood or mobilized peripheral blood, yielding not only αβ but also γδ T cells with a polyclonal T-cell receptor (TCR) repertoire. In contrast, noncorrected RAG1-deficient HSPCs from 3 RAG1-SCID patients show a developmental arrest before or at the aberrant CD4+CD8dim double-positive stage, characterized by minimal or absent CD1a upregulation and CD7 downregulation, absence of TCRβ rearrangement, and only partial TCRγ and TCRδ rearrangement. Lentiviral RAG1 gene addition using the clinical vector rescues T-cell development in these patient-derived HSPCs and restores TCR repertoire diversity. These findings highlight the ATO system as a valuable model for dissecting human T-cell development and for the preclinical development and evaluation of gene therapy.
引用
- Meng X, Melsen JE, van der Holst R, et al. RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids. Blood Adv. 2025. PMID: 40829114. doi:10.1182/bloodadvances.2025016970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。